198 related articles for article (PubMed ID: 29720705)
21. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT).
Beksac M; Kröger N; Byrne JL; Ganser A; Yeğin ZA; Schönland S
Bone Marrow Transplant; 2021 Mar; 56(3):529-531. PubMed ID: 32741961
[No Abstract] [Full Text] [Related]
23. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation (EBMT).
Schmitz N; Gratwohl A; Goldman JM
Bone Marrow Transplant; 1996 Apr; 17(4):471-7. PubMed ID: 8722341
[TBL] [Abstract][Full Text] [Related]
24. Recognition of Hematopoietic Stem Cell Transplantation and Cellular Therapy Expertise to Promote Care Accessibility: A Formally Credentialed Area of Focused Competence in Canada.
Lachance S; Gomes MM; Bambace NM; Bittencourt H; Lepic K; Shafey M; Karpinski J; Guilcher GMT
Transplant Cell Ther; 2021 Sep; 27(9):702-706. PubMed ID: 34153503
[TBL] [Abstract][Full Text] [Related]
25. Blood and marrow transplantation activity in Europe 1995. European Group for Blood and Marrow Transplantation (EBMT).
Gratwohl A; Hermans J; Baldomero H
Bone Marrow Transplant; 1997 Mar; 19(5):407-19. PubMed ID: 9052905
[TBL] [Abstract][Full Text] [Related]
26. Blood and marrow transplantation activity in Europe 1996. European Group for Blood and Marrow Transplantation (EBMT).
Gratwohl A; Passweg J; Baldomero H; Hermans J
Bone Marrow Transplant; 1998 Aug; 22(3):227-40. PubMed ID: 9720735
[TBL] [Abstract][Full Text] [Related]
27. Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT).
Gratwohl A; Passweg J; Baldomero H; Hermans J
Bone Marrow Transplant; 1999 Aug; 24(3):231-45. PubMed ID: 10456992
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT.
Pavlů J; Labopin M; Zoellner AK; Sakellari I; Stelljes M; Finke J; Fanin R; Stuhler G; Afanasyev BV; Bloor AJ; Anagnostopoulos A; Mohty M; Giebel S; Nagler A
Cancer; 2017 Jun; 123(11):1965-1970. PubMed ID: 28211939
[TBL] [Abstract][Full Text] [Related]
29. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
30. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
Shenoy S; Gaziev J; Angelucci E; King A; Bhatia M; Smith A; Bresters D; Haight AE; Duncan CN; de la Fuente J; Dietz AC; Baker KS; Pulsipher MA; Walters MC
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1313-1321. PubMed ID: 29653206
[TBL] [Abstract][Full Text] [Related]
31. Haploidentical stem cell transplantation-bone marrow vs peripheral blood.
Gulbas Z
Transfus Apher Sci; 2018 Apr; 57(2):168-170. PubMed ID: 29764770
[TBL] [Abstract][Full Text] [Related]
32. Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation.
Holbro A; Baldomero H; Lanza F; Chabannon C; Snowden JA; Buser A; Infanti L; Worel N; Sureda A; Badoglio M; Passweg J; Bonini C;
Cytotherapy; 2018 Mar; 20(3):453-460. PubMed ID: 29352666
[TBL] [Abstract][Full Text] [Related]
33. American Society for Transplantation and Cellular Therapy Guidelines for Fellowship Training in Hematopoietic Cell Transplantation and Immune Effector Cell Therapy.
Jain T; Knight T; Alencar MC; Davis L; Rao K; Im A; Malone AK;
Transplant Cell Ther; 2022 Mar; 28(3):125-133. PubMed ID: 34954294
[TBL] [Abstract][Full Text] [Related]
34. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years.
Passweg JR; Baldomero H; Chabannon C; Basak GW; de la Cámara R; Corbacioglu S; Dolstra H; Duarte R; Glass B; Greco R; Lankester AC; Mohty M; Peffault de Latour R; Snowden JA; Yakoub-Agha I; Kröger N;
Bone Marrow Transplant; 2021 Jul; 56(7):1651-1664. PubMed ID: 33623153
[TBL] [Abstract][Full Text] [Related]
35. Irradiated blood components.
Benson K; Elfenbein G
Am J Clin Pathol; 1997 Feb; 107(2):251; author reply 253-4. PubMed ID: 9024077
[No Abstract] [Full Text] [Related]
36. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation.
Ruutu T; van Biezen A; Hertenstein B; Henseler A; Garderet L; Passweg J; Mohty M; Sureda A; Niederwieser D; Gratwohl A; de Witte T
Bone Marrow Transplant; 2012 Nov; 47(11):1459-64. PubMed ID: 22410750
[TBL] [Abstract][Full Text] [Related]
37. Indications for hematopoietic stem cell transplantation.
Hołowiecki J
Pol Arch Med Wewn; 2008 Nov; 118(11):658-63. PubMed ID: 19140570
[TBL] [Abstract][Full Text] [Related]
38. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.
Elsawy M; Sorror ML
Bone Marrow Transplant; 2016 Oct; 51(10):1283-1300. PubMed ID: 27272454
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
40. 'The Mexican approach' to conduct NST.
Ruiz-Argüelles GJ
Eur J Haematol; 2001; 67(5-6):335. PubMed ID: 11872085
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
